JAZZ PHARMACEUTICALS ($JAZZ) posted quarterly earnings results on Wednesday, November 5th. The company reported earnings of $8.13 per share, beating estimates of $5.93 by $2.20. The company also reported revenue of $1,126,110,000, missing estimates of $1,130,691,165 by $-4,581,165.
You can see Quiver Quantitative's $JAZZ stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
JAZZ PHARMACEUTICALS Insider Trading Activity
JAZZ PHARMACEUTICALS insiders have traded $JAZZ stock on the open market 13 times in the past 6 months. Of those trades, 4 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $JAZZ stock by insiders over the last 6 months:
- SEAMUS MULLIGAN has made 4 purchases buying 101,621 shares for an estimated $9,993,081 and 0 sales.
- BRUCE C COZADD has made 0 purchases and 9 sales selling 14,500 shares for an estimated $1,855,040.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
JAZZ PHARMACEUTICALS Hedge Fund Activity
We have seen 235 institutional investors add shares of JAZZ PHARMACEUTICALS stock to their portfolio, and 286 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP added 1,200,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $127,344,000
- MILLENNIUM MANAGEMENT LLC added 640,250 shares (+2985.3%) to their portfolio in Q2 2025, for an estimated $67,943,330
- CAPITAL WORLD INVESTORS added 616,728 shares (+32.0%) to their portfolio in Q2 2025, for an estimated $65,447,175
- LOGOS GLOBAL MANAGEMENT LP added 450,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $47,754,000
- AQR CAPITAL MANAGEMENT LLC added 304,463 shares (+62.1%) to their portfolio in Q2 2025, for an estimated $32,309,613
- TWO SIGMA INVESTMENTS, LP removed 299,301 shares (-86.9%) from their portfolio in Q2 2025, for an estimated $31,761,822
- FULLER & THALER ASSET MANAGEMENT, INC. added 297,948 shares (+22.4%) to their portfolio in Q2 2025, for an estimated $31,618,241
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
JAZZ PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $JAZZ in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 10/27/2025
- Morgan Stanley issued a "Overweight" rating on 09/24/2025
- Goldman Sachs issued a "Buy" rating on 08/29/2025
- Needham issued a "Buy" rating on 08/28/2025
- RBC Capital issued a "Outperform" rating on 08/28/2025
- Truist Securities issued a "Buy" rating on 08/28/2025
To track analyst ratings and price targets for JAZZ PHARMACEUTICALS, check out Quiver Quantitative's $JAZZ forecast page.
JAZZ PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $JAZZ recently. We have seen 6 analysts offer price targets for $JAZZ in the last 6 months, with a median target of $192.0.
Here are some recent targets:
- Jessica Fye from JP Morgan set a target price of $199.0 on 10/27/2025
- Jeffrey Hung from Morgan Stanley set a target price of $180.0 on 10/20/2025
- Madhu Kumar from Goldman Sachs set a target price of $185.0 on 08/29/2025
- Ami Fadia from Needham set a target price of $202.0 on 08/28/2025
- Leonid Timashev from RBC Capital set a target price of $151.0 on 08/28/2025
- Gregory Fraser from Truist Securities set a target price of $205.0 on 08/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
